ORYZON announces formal grant of key European patent for vafidemstat

by Oryzon Genomics

2 months ago
borderline personality disorder (BPD), schizophrenia, Vafidemstat, EP3661510B1

Oryzon announced today that the European Patent Office (EPO) has now formally granted Oryzon’s European patent EP3661510B1, titled “Methods of treating behavior alterations” related to vafidemst...

New Avenues to Developing Personalized Treatments for Schizophrenia

by IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

6 months ago
G proteins, 2A serotonin receptor, Schizophrenia

It has been demonstrated, for the first time, the role of two proteins in the activation and deactivation of the system through which drugs act against schizophrenia symptoms. These two proteins are p...

A genomic study will help to predict which patients with schizophrenia might benefit from early treatment with clozapine

by Hospital de la Santa Creu i Sant Pau

2 years ago
clozapine, polygenic risk, schizophrenia

It has been bring to the table a novel genomic tool that would help to predict which patients will respond poorly to conventional treatments and, therefore, would be early candidates for treatment wit...

People with schizophrenia who participate in clinical trials may not be representative of the population suffering from this disease

by Instituto de Investigación e Innovación Parc Taulí

3 years ago
schizophrenia

An international study led by I3PT notes that clinical trials may account for only about one-fifth of people in the real world with schizophrenia spectrum disorders, and points out that new studies sh...

ORYZON enrolls first patient in EVOLUTION, a Phase IIb clinical trial with vafidemstat in schizophrenia

by Oryzon Genomics

3 years ago
Oryzon Genomics, EVOLUTION, Schizophrenia, Vafidemstat

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today...

ORYZON receives approval to start EVOLUTION Phase IIb trial with vafidemstat in schizophrenia

by Oryzon Genomics

3 years ago
Vafidemstat, Oryzon Genomics, biopharmaceutical, Clinical Trial, schizophrenia

ORYZON Launches Pioneering Schizophrenia Precision Medicine Study In Collaboration With Columbia Psychiatry

by Oryzon Genomics

4 years ago
neuropsychiatric symptoms, Schizophrenia, Precision Medicine

Goal is to characterize the neuropsychiatric symptoms of patients harboring disease-causing SETD1A gene mutations Also includes fundamental research in preclinical SETD1A models

The lack of interaction between two neuronal receptors is a determining factor in schizophrenia

by Universitat de Barcelona

4 years ago
neuronal, schizophrenia, neuropsychiatric disorder, dopaminergic

Schizophrenia is a severe neuropsychiatric disorder which is presented through hallucinations, delusions and behavioural and motor disorders. Historically, this disease was associated with an overacti...

ORYZON initiates a new project to explore the efficacy of vafidemstat in the treatment of schizophrenia

by Oryzon Genomics

5 years ago
mental health, schizophrenia, vafidemstat, VHIR

Significant differences exist among neurons expressing dopamine receptors

by Universitat Autònoma de Barcelona (UAB)

5 years ago
schizophrenia, Parkinson, dopamine, neurons

An international collaboration, which included the involvement of the research team from the Institut de Neurociències (INC) and from the Department of Cellular Biology, Physiology and Immunology, ha...

Experts in G protein-coupled receptors meet at the UB to discuss new pharmacological perspectives

by Hospital Universitari de Bellvitge

5 years ago
protein, pharmaco, Parkinson, schizophrenia

Within the framework of the X Esteve Foundation Discussion Group, on February 13th and 14th the tenth meeting of the working group on new advances in the field of G-protein coupled receptors (GPCR) wa...

Biological diagnosis of schizophrenia: the future

by Fundació Clínic per a la Recerca Biomèdica

5 years ago
diagnosis, schizophrenia, mental health, biomarker

Schizophrenia is a very heterogeneous disease, patients who suffer this may present a variety of symptoms. In addition, there is currently no analytical or imaging test that confirms the diagnosis. Th...